Financial Performance - LINZESS U S net sales reached $315 million in Q3 2025, a 40% year-over-year increase, driven by improved net pricing and a 12% year-over-year growth in EUTRx demand[11] - Ironwood generated $40 million in GAAP net income and $82 million in adjusted EBITDA in Q3 2025[11] - The company's share of net profit from the LINZESS U S brand collaboration was $119 515 million for the three months ended September 30, 2025[15] - Ironwood's collaborative arrangements revenue was $119 646 million for the three months ended September 30, 2025[15] - Ironwood ended Q3 2025 with $140 million in cash and cash equivalents[11] Guidance and Expectations - Full-year LINZESS U S net sales guidance was raised to $860 - $890 million, and total revenue guidance to $290 - $310 million[11] - Adjusted EBITDA guidance was raised to greater than $135 million[11] LINZESS Performance - LINZESS extended unit (EUTRx) and new to brand (NBRx) prescriptions each grew 12% year-over-year in Q3 2025[12] - LINZESS U S net product sales as reported by AbbVie were $314 856 million for the three months ended September 30, 2025[15] Strategic Developments - In November 2025, the FDA approved LINZESS as the first drug for the treatment of children 7 years and older with irritable bowel syndrome with constipation (IBS-C)[11] - The company plans to align with the FDA in Q4 2025 on confirmatory Phase 3 trial design for Apraglutide, with trial initiation expected in 1H 2026[7]